$ENVB

Enveric Biosciences (ENVB) received a U.S. patent allowance for its EVM401 Series of non-hallucinogenic mescaline-derived compounds, designed to treat PTSD and other psychiatric disorders. This is the third patent in the series, covering novel methylone-inspired compounds. The company aims to strengthen its intellectual property portfolio and develop treatments that promote neuroplasticity without hallucinogenic effects.

Enveric Biosciences (ENVB) announced its CEO will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026. The presentation will update progress on EB-003, including IND-enabling studies and preclinical data. Dr. Tucker will also discuss the EVM401 Series and meet with investors.

Enveric Biosciences (NASDAQ: ENVB) reported Q2 2026 results and a corporate update. The company said EB-003 IND-enabling work advanced, including genotoxicity studies, and preclinical assays suggested a non-hallucinogenic and non-photoreactive profile. Enveric also received USPTO patent approvals and raised about $5.0M gross in a private placement plus $1.5M from warrant exercises. Net loss was $3.0M, cash $8.3M.

Enveric Biosciences, Inc. (ENVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 EB-003 Development Highlights: ● Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003

Enveric Biosciences said new preclinical tests using the Promega GloSensor cAMP live-cell assay show its lead psychiatric candidate EB-003 stays within a non-hallucinogenic profile versus hallucinogen and reference compounds. The company plans to advance EB-003 toward first-in-human Phase 1 trials. ENVB shares were down 7.69% to $1.56 premarket.

Enveric Biosciences Inc. (NASDAQ: ENVB) has successfully raised up to $13.9 million through a private placement, with an initial $5 million received upon closing. This funding, along with an additional $1.5 million from warrant exercises, will primarily support the preclinical development of its lead product candidate, EB-003, and facilitate the submission of an Investigational New Drug application. Despite a low GF Score™ of 28, indicating potential profitability challenges, the company boasts strong financial strength.

This page on TradingKey provides real-time and historical financial data for Enveric Biosciences Inc (ENVB), including its current stock price, market cap, and after-hours trading information. It also offers sections for financials, discussions, and analysis, inviting users to log in and comment. The platform highlights its features like "One powerful score" for smarter investment decisions and provides various tools and educational resources.

Enveric Biosciences (NASDAQ: ENVB) stock surged nearly 30% after the FDA outlined steps to accelerate the development of serotonin-2A agonists and psychedelic-based therapies for mental health disorders. The FDA cleared the first U.S. trial for an ibogaine derivative to treat alcohol use disorder and will issue national priority vouchers to companies studying psychedelic compounds. This proactive stance follows a White House directive and focuses on fast-tracking promising treatments, especially those with Breakthrough Therapy designation.

Enveric Biosciences (ENVB) stock surged 134.4% following the announcement of its at-the-market private placement closing. This includes a substantial warrant package, which likely contributed to increased trading interest, short-covering, and momentum buying in the small-cap biotech. The private placement secured $5.0 million upfront, with potential for an additional $8.9 million if warrants are fully exercised.

Enveric Biosciences announced that Gilgamesh Pharmaceuticals has withdrawn a challenge against its patent, leaving no remaining challenges. The patent concerns new chemical versions of psilocybin for mental health conditions. ENVB stock rose over 4% on the news, despite a significant year-to-date and 12-month decline.